EP1740190A1 - Utilisation d'un melange pour produire un agent servant a traiter un cartilage defectueux ou degenere in vivo et pour produire un substitut de cartilage naturel in vitro - Google Patents

Utilisation d'un melange pour produire un agent servant a traiter un cartilage defectueux ou degenere in vivo et pour produire un substitut de cartilage naturel in vitro

Info

Publication number
EP1740190A1
EP1740190A1 EP04717539A EP04717539A EP1740190A1 EP 1740190 A1 EP1740190 A1 EP 1740190A1 EP 04717539 A EP04717539 A EP 04717539A EP 04717539 A EP04717539 A EP 04717539A EP 1740190 A1 EP1740190 A1 EP 1740190A1
Authority
EP
European Patent Office
Prior art keywords
substances
group
cartilage
solvent
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04717539A
Other languages
German (de)
English (en)
Inventor
Markus Wimmer
Mauro Alini
Thomas Kaup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthes GmbH
Original Assignee
Synthes GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthes GmbH filed Critical Synthes GmbH
Publication of EP1740190A1 publication Critical patent/EP1740190A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Definitions

  • the invention relates to the use of a mixture for the production of an agent for the treatment of defective or degenerated cartilage in vivo according to the preamble of claim 1 and to the use of this mixture in the production of natural cartilage replacement in vitro according to claim 9.
  • scaffolds made of polymer materials which are colonized with chondrocytes. They serve as a carrier material for the chondrocytes and are available as resorbable or non-resorbable material.
  • scaffolds made from natural and synthetically resorbable carrier materials have been developed and tested. It was found that these in vitro grown cartilage-like constructions do not achieve the biochemical or biomechanical properties of in vivo tissues.
  • osteochondral grafts are inserted into the cartilage defect and anchored in the subchondral bone.
  • organ donor and host are one and the same person
  • in the second case they are different, but from the same species.
  • cylindrical cartilage pins are removed from the donor region together with the subchondral bone and anchored in the defect zone using a pre-made press fit.
  • a pin or several pins are used to close the damaged surface.
  • Chondrocyte transplantation removes chondrocytes from regions of the knee that are less stressed.
  • the removed cells are grown in nutrient solution within 14 to 21 days. After culturing, the cells are injected into the region of the defect and covered with a piece of periosteum or perichondrium. After 2 years, a biopsy can show that hyaline cartilage has formed. In one study, the clinical outcome of 14 out of 16 patients was described as good to very good. A study in Sweden with 400 patients showed comparable results.
  • articular cartilage consists on the one hand in the absorption and distribution of forces which occur when the joint is loaded and on the other hand in the provision of a lubricating surface which prevents the abrasion and degradation of the joint.
  • the first function is ensured by a unique composition and structure of the extracellular matrix, the second Function, however, depends on a functional cartilage-synovial interface. These functions are disrupted, particularly in patients with degeneratively altered or otherwise affected cartilage surfaces.
  • the invention seeks to remedy this.
  • the invention is based, on the one hand, to provide an agent for treating defective or degenerated cartilage in vivo and, on the other hand, to provide an improved production of natural cartilage replacement in vitro, in particular for cartilage defects in the joint area.
  • the invention achieves the stated object with a means which has the features of claim 1 and a use of this means which has the features of claim 9.
  • the lubricin is the lubricating glycoprotein-1 (LGP-1), which is produced from the same gene as the megakaryocyte stimulation factor (MSF) by alternative splicing.
  • Lubricin has a molecular weight of approximately 230 kDa (purified form in human synovial fluid) and is highly glycosylated.
  • Proteoglycan 4 is the name of the surface zone protein (SZP), which is obtained from the MSF gene by alternative splicing. It has a molecular weight of approximately 340 kDa (from human articular cartilage) and carries several oligosaccharide residues and glycosaminoglycan chains. It has been shown that the use of SZP and similar substances (group A) in the mixture according to the invention not only shows a strong lubricating effect, but also acts as a chondroprotective molecule, which provides protection for the deep-lying cartilage cells.
  • SZP surface zone protein
  • SZP was originally isolated and purified from culture fluids from explants that originated from the surface zone of bovine cartilage. SZP can be synthesized by chondrocytes in the surface zone, but not from the middle and lower zones.
  • the hyaluronic acid consists of glucuronic acid and acetylglucosamine, which build up the disaccharide hyalubironic acid. Due to its filiform, unbranched molecular structure, hyaluronic acid forms highly viscous solutions. Although hyaluronic acid has no direct lubricating properties, it is important for the theological behavior of the synovial fluid by setting a suitable viscosity level, which prevents the synovial fluid from flowing out during the stress phase of the joint.
  • the improved lubrication can be expected to reduce cartilage degeneration and reduce abrasion of the artificial joint. This increases the lifespan of the implant and revision can be prevented or delayed.
  • the phospholipids used are surface-active in nature.
  • the resulting interface lubrication causes less severe cartilage damage in the further course.
  • the hyaluronic acid to be used advantageously has a molecular weight of at least 1x10 6 Da.
  • the weight ratio A / B between the substances of group A [Lubricin, Proteoglycan 4 (PRG4) and phospholipids (SAPL)] and of group B [hyaluronic acid, glycosaminoglycan and derivatives of these substances] is advantageously in the range from 0.05 and 0.40 , preferably in the range of 0.08 and 0.25.
  • the solvent to be used is advantageously a Ringer's solution, preferably a physiological saline solution.
  • the concentration of the group A substances in the solvent is preferably in the range from 0.02 to 0.05% by weight and that of the group B substances in the range from 0.2 to 0.4% by weight.
  • B) hyaluronic acid, glycosaminoglycan and derivatives of these substances; dissolved in a solvent, can also be used to make natural cartilage replacements in vitro.
  • Such a mixture can also be used for a method for producing a cartilage replacement material for cartilage defects in the joint area, wherein an open-pore, elastic cell carrier body is populated with chondrocytes in its pores and this mixture is dissolved in a physiologically acceptable solvent and brought into contact with the chondrocytes.
  • the solvent is preferably moved over the cell carrier body in a laminar flow.
  • an axial and a rotary force are simultaneously applied to the cell carrier body by means of a joint ball-like device.
  • the rotation of the joint ball-like device is preferably carried out about two axes orthogonal to one another.
  • a patient was injected with a solution containing 6 mg lubricin and 45 mg hyaluronic acid into the closed joint capsule.
  • the solvent consisted of 25 ml of physiological saline (Ringer's solution), to which 5% human serum from the same patient was added.
  • the endoscopic examination after physiotherapeutic therapy of the joint showed an improved healing of the cut surfaces between the host and the donor tissue.
  • the patient was free of pain and was able to carry out his usual activities.
  • Chondrocytes were isolated from the weightless region of the defect surface of the knee joint and implanted directly into an open pore, elastic cell support body.
  • the cell carrier body consisted of a cylindrical, porous, biodegradable polyurethane frame with an identical size of 8 mm x 4 mm to the defect. The cell density was 25-30 x 10 6 .
  • the cell carrier body which is populated with chondrocytes in its pores, was modified in “Dulbecco's Eagles medium "(DMEM), which 5% human serum (the same
  • L-alanine (0.89 mg / L), L-asparagine (1.32 mg / L), L-aspartic acid (1.33 mg / L), L-
  • the mechanical load on the cell carrier body was carried out in a so-called
  • Bioreactor system in which the cell carrier body was exposed to the action of a sphere, so that both rotational and axial forces on the
  • Cell carrier body could be applied. A mechanical stress of this type was applied to the cell carrier body twice a day. In a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un mélange comprenant une ou plusieurs substances du groupe A) qui rassemble lubricine, protéoglycane 4 (PRG4) et phospholipide (SAPL), et une ou plusieurs substances du groupe B) qui rassemble acide hyaluronique, glycosaminoglycane et des dérivés de ces substances, en dissolution dans un solvant, et servant à produire un agent pour traiter un cartilage défectueux ou dégénéré in vivo. Le mélange selon l'invention peut également être utilisé pour produire un substitut de cartilage naturel in vitro.
EP04717539A 2004-03-05 2004-03-05 Utilisation d'un melange pour produire un agent servant a traiter un cartilage defectueux ou degenere in vivo et pour produire un substitut de cartilage naturel in vitro Withdrawn EP1740190A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2004/000131 WO2005084684A1 (fr) 2004-03-05 2004-03-05 Utilisation d'un melange pour produire un agent servant a traiter un cartilage defectueux ou degenere in vivo et pour produire un substitut de cartilage naturel in vitro

Publications (1)

Publication Number Publication Date
EP1740190A1 true EP1740190A1 (fr) 2007-01-10

Family

ID=34916964

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04717539A Withdrawn EP1740190A1 (fr) 2004-03-05 2004-03-05 Utilisation d'un melange pour produire un agent servant a traiter un cartilage defectueux ou degenere in vivo et pour produire un substitut de cartilage naturel in vitro

Country Status (4)

Country Link
US (1) US20070275032A1 (fr)
EP (1) EP1740190A1 (fr)
CA (1) CA2558497A1 (fr)
WO (1) WO2005084684A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5862199A (en) 1998-09-11 2000-04-03 Michael Raschke Biologically active implants
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
JP2008507553A (ja) * 2004-07-23 2008-03-13 ミューコサル セラピューティクス リミテッド ライアビリディ カンパニー 粘性補給のための組成物および方法
FR2922219B1 (fr) 2007-10-10 2009-12-04 Maco Pharma Sa Methode pour stimuler la proliferation de cellules differenciees appartenant au lignage chondrogenique
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
ES2530723T3 (es) * 2008-05-07 2015-03-04 Univ California Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular
US8980840B2 (en) 2009-01-13 2015-03-17 Schepens Eye Research Institute Therapeutic modulation of vaginal epithelium boundary lubrication
US9730865B2 (en) 2009-05-22 2017-08-15 Lubris, Llc Application and uses of PRG4 and therapeutic modulation thereof
US20120114755A1 (en) * 2009-06-22 2012-05-10 Mayo Foundation For Medical Education And Research Methods and materials for tissue repair
CA2771110C (fr) 2009-08-13 2019-02-26 Singularis, Inc. Traitement de prg4 pour cystite interstitielle
ES2627103T3 (es) * 2010-01-19 2017-07-26 Lubris Llc Composiciones de cuidado bucal y métodos
US8617240B2 (en) 2010-11-17 2013-12-31 Charles D. Hightower Moldable cushion for implants
CN102552996A (zh) * 2010-12-07 2012-07-11 宁小静 人体润滑剂
EP2776044A1 (fr) * 2011-11-08 2014-09-17 Danmarks Tekniske Universitet Compositions pharmaceutiques comprenant des lubrifiants pour prévenir ou réduire le descellement aseptique chez un sujet

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036056A (en) * 1987-07-08 1991-07-30 Martin Kludas Methods for treating damaged corneal, uterine, or cartilage tissue
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
US5171273A (en) * 1989-01-13 1992-12-15 University Of Medicine And Dentistry Of New Jersey Synthetic collagen orthopaedic structures such as grafts, tendons and other structures
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5515590A (en) * 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5891558A (en) * 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
AU3203599A (en) * 1998-04-01 1999-10-18 Parallax Medical, Inc. Pressure applicator for hard tissue implant placement
WO2001068800A1 (fr) * 2000-03-11 2001-09-20 The Trustees Of Columbia University In The City Of New York Bioreacteur destine a la production de tissu cartilagineux fonctionnel
ES2301547T3 (es) * 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
US20030180948A1 (en) * 2000-12-29 2003-09-25 Hutchins Jeff T. Superficial zone protein and methods of making and using same
JP4990446B2 (ja) * 2001-05-28 2012-08-01 電気化学工業株式会社 関節症治療用注入剤
AU2002354911B2 (en) * 2001-07-16 2007-08-30 Depuy Products, Inc. Meniscus regeneration device and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005084684A1 *

Also Published As

Publication number Publication date
WO2005084684A1 (fr) 2005-09-15
CA2558497A1 (fr) 2005-09-15
US20070275032A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
DE69531779T2 (de) Herstllung von autogenen körperersatzteilen
DE69333556T2 (de) Injizierbare keramische Zusammensetzungen sowie Verfahren für ihre Herstellung und Verwendung
DE60020807T2 (de) Verformbare Paste zum Füllen von Knochendefekten
DE69927512T2 (de) Verwendung von op-1 zur herstellung einer pharmazeutischen zusammensetzung zur reparatur von nicht-gelenksknorpeldefekten eines säugers
DE69434122T2 (de) Osteogenisches produkt und verwendung
DE69534038T2 (de) Vorrichtung und verfahren zum in-vivo-züchten von verschiedenen gewebezellen
DE60023754T2 (de) Künstlicher kalciumphosphatknochen als osteokonduktives und biologisch abbauba res knochenersatzmaterial
DE69835810T2 (de) OSTEOGENE VORRICHTUNGEN UND VERFAHREN ZU IHRER VERWENDUNG ZUR FöRDERUNG DER KNOCHENHEILUNG
DE60207198T2 (de) Transplantate für die wiederherstellung von osteochondralen schäden
EP0520237B1 (fr) Matériau de prothèse osseuse contenant des facteurs de croissance de fibroblastes
EP0605799B1 (fr) Endoprothèse creuse avec un remplissage favorisant la croissance osseuse
DE69922312T2 (de) Keramikmaterial zur Osteoinduktion enthaltend Mikroporen an der Öberfläche von Makroporen
KR940007920B1 (ko) 온혈 동물에서 뼈 골절 및 골절술의 치료와 치유증진을 위한 방법
EP2272467B1 (fr) Implant surélevé pour la reconstruction de défauts du ménisque ou de défauts partiels du ménisque
WO2005084684A1 (fr) Utilisation d'un melange pour produire un agent servant a traiter un cartilage defectueux ou degenere in vivo et pour produire un substitut de cartilage naturel in vitro
JP5739894B2 (ja) 軟骨組織修復用組成物及びその製造方法
EP1732618A1 (fr) Procede pour realiser un materiau d'implant osseux
DE112016001386B4 (de) Kohlenstoffpartikel und Komposite derselben für die Regeneration von Skelettmuskelgewebe und Weichgewebe
EP3733198B1 (fr) Composition pour la régénération de cartilage fibreux ou de cartilage élastique humain
CN111346262B (zh) 一种用于促进腱骨愈合的可注射钙磷陶瓷及其制备方法与应用
EP1846055B1 (fr) Procede de production d'un revetement d'implant osteoinductif-antiseptique
KR20120007513A (ko) 연골 복구
DE102009032216B4 (de) Spacer-Implantat zur Behandlung von menschlichen oder tierischen Gelenkknorpelschäden
DE60029492T2 (de) Verformbare Knochen-Zusammensetzung zum Füllen von Knochendefekten
Naderi et al. Biomaterials and structural fat grafting

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060721

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB LI

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): CH DE FR GB LI

17Q First examination report despatched

Effective date: 20070529

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071009